Antiplatelet Therapy for Vascular Disease
(CAPTT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Patients on dual antiplatelet therapy )aspirin plus a P2Y12 inhibitor \[clopidogrel, prasugrel, or ticagrelor\]) undergoing screening or surveilance colonoscopy are at increased risk for bleeding from the procedure. Patients are ussually asked to stop the P2Y12 inhibitor for the procedure. Currently, recommendation is that patients only on a P2Y12 inhibitor be changes to aspirin for the procedure. This pilot study will evaluate if there is a large difference in bleeding between patients only taking aspirin compared with patients only taking a P2Y12 inhibitor. Patinets who participate will randomly be randomly asked to stop either aspirin or the P2Y12 inhibitor 1 week before the procedure. Periprocedural bleeding and bleeding after the procedure for iup to 30 days.
Will I have to stop taking my current medications?
Yes, if you are taking both aspirin and a P2Y12 inhibitor, you will be asked to stop either aspirin or the P2Y12 inhibitor one week before the procedure.
Is antiplatelet therapy safe for humans?
Antiplatelet therapy, including drugs like aspirin, clopidogrel, prasugrel, and ticagrelor, is generally safe for humans but can increase the risk of bleeding. Prasugrel may cause more major bleeding compared to clopidogrel and ticagrelor, so it is often recommended for patients with a low risk of bleeding.12345
How is the drug combination of aspirin and P2Y12 inhibitors unique for treating vascular disease?
The combination of aspirin and newer P2Y12 inhibitors like prasugrel and ticagrelor is unique because it offers more rapid and consistent platelet inhibition compared to older treatments like clopidogrel, which can lead to better prevention of blood clots in patients with vascular disease. However, prasugrel may have a higher risk of bleeding in certain patients, such as those over 75 years old or with low body weight.678910
What evidence supports the effectiveness of the drug combination of aspirin and P2Y12 inhibitors for vascular disease?
Research shows that combining aspirin with P2Y12 inhibitors like clopidogrel, prasugrel, or ticagrelor is effective in reducing major cardiovascular events in patients with acute coronary syndromes (heart-related conditions caused by sudden reduced blood flow to the heart). This combination helps prevent blood clots, although it may increase the risk of bleeding.5781112
Are You a Good Fit for This Trial?
This trial is for patients with vascular diseases who are on dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) and need a colonoscopy. They should be able to stop one of their medications before the procedure. Specific inclusion or exclusion criteria were not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomly assigned to stop either aspirin or the P2Y12 inhibitor 1 week before the colonoscopy procedure
Follow-up
Participants are monitored for periprocedural bleeding and bleeding after the procedure
What Are the Treatments Tested in This Trial?
Interventions
- Aspirin
- P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
Aspirin is already approved in European Union, United States, Canada, China for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ochsner Health System
Lead Sponsor